Should the Food and Drug Administration Limit Placebo-Controlled Trials? by Max Goodman, Connor Pedersen

“…Condition Two: Negligible Harm from Delayed Treatment The International Ethical Guidelines for Biomedical Research Involving Human Subjects argues that placebos are acceptable if there is only “temporary discomfort or a delay in relief of symptoms,” a stipulation that the FDA follows. …”
Get full text

Addressing Shortcomings in Contingency Standards of Care by Alexander Quan

“…However, the simplest solution is to encourage the creation of ethics guidance or protocols for contingency allocation at the hospital level. …”
Get full text